Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors.

ABSTRACT:

Background

Although breast cancer survivors are at risk for cardiovascular disease (CVD) from treatment late effects, evidence to inform long-term and age-specific cardiovascular surveillance recommendations is lacking.

Methods

We conducted a retrospective cohort study of 10 211 women diagnosed with first primary unilateral breast cancer in Kaiser Permanente Washington or Colorado (aged 20 years and older, survived ≥1 year). We estimated multivariable adjusted hazard ratios (HRs) for associations between initial chemotherapy regimen type (anthracycline and/or trastuzumab, other chemotherapies, no chemotherapy [referent]) and CVD risk, adjusted for patient characteristics, other treatments, and CVD risk factors. Cumulative incidence was calculated considering competing events

SUBMITTER: Vo JB 

PROVIDER: S-EPMC11308182 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature